Strategy | Cells | Target locus | Selection | Editing pre-enrichment | Editing post-enrichment | Fold increase | Ref. |
---|---|---|---|---|---|---|---|
PEAR | HEK293T | FANCF | FACS | N.A | 76% | N.A | [183] |
PEAR | K562 | FANCF | FACS | N.A | 62% | N.A | [183] |
PEAR | U2OS | EMX1 | FACS |  ~ 15% |  ~ 40% | 2.67-fold | [183] |
PEAR | HUES9 | FANCF | FACS | Â | 28% | 7.8-fold | [183] |
PEAR | HEK293T | HEK3/RUNX1/HEXA/ EMX1/DNMT/FANCF/ HBB/PRNP | FACS | N.A | Up to 84% | 2.1- to 4.6-fold | [183] |
Marker-free co-selection | K562 | RNF2/RUNX1/FANCF/ EMX1 | Drug selection | N.A | 83% | N.A | [184] |
Marker-free co-selection | HeLa | RNF2/RUNX1/FANCF/ EMX1 | Drug selection |  < 1% | 26–59% |  > 26-fold | [184] |
Marker-free co-selection | K562 | RUNX1 and FANCF | Drug selection | N.A | 81% (RUNX1) and 64% (FANCF) | N.A | [184] |
Marker-free co-selection | K562 | EMX1 and RUNX1 | Drug selection | N.A | 63% (EMX1) and 78% (RUNX1) | N.A | [184] |
Marker-free co-selection | HeLa | MTOR | Drug selection | 4–17% | 30–78% | 4- to 8-fold | [184] |
Marker-free co-selection | U2OS | MTOR | Drug selection | N.A | 74–89% | N.A | [184] |